Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie - 1 Jan 2016

Kamal Adina Maria, MitruŢ Paul, Kamal Kamal Constantin, Tica Oana Sorina, Niculescu Mihaela, Alexandru Dragoş Ovidiu, Tica Andrei Adrian

Abstract excerpt

Globally, over 4% of the world population is affected by hepatitis C virus (HCV) infection. The current standard of care for hepatitis C infection is combination therapy with pegylated interferon and ribavirin for 48 weeks, which yield a sustained virological response in only a little over half of the patients with genotype 1 HCV. We investigated the clinical importance of pharmacogenetics in treatment efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemoglobins
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Interleukins

Share to Pharmacogenetics

Share to Polyethylene Glycols

Share to Pyrophosphatases

Share to Ribavirin

Source

Identifiers

PMID: 27833958

Genes

ITPA
IFNL3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.PMID 27833958Read ↗

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.Semantic proximity Read ↗

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.Semantic proximity Read ↗

Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment.Semantic proximity Read ↗

ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.Semantic proximity Read ↗

Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.Semantic proximity Read ↗

ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.Semantic proximity Read ↗

Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.Semantic proximity Read ↗

The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors.Semantic proximity Read ↗

Pharmacogenetics of hepatitis CSemantic proximity Read ↗

Pharmacogenetics of ribavirin-induced anemia in HCV patients.Semantic proximity Read ↗

Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.